Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three diversified platforms currently address five different diseases. The platforms include Cabaletta, which is a platform for diseases characterized by mutated proteins; BBrm platform is a […]
TRIL – Preparing For The Next Move Upward
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat” signal to macrophages. High expression of CD47 by tumor cells has been correlated with more aggressive disease and poor survival. SIRPαFc is initially being developed […]
BMY – Is the Technical Correction Done ?
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high $69.20 in March, 20th 2015, getting a boost from the fastest FDA approval I ever seen. On Febreuary 27th 2015 the FDA granted Priority Review […]
Adamas Pharmaceuticals – Volatility Squeeze Action
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas pharmaceutical had its initial public offering last year April 10th, the closing of its IPO of 3 million shares at a public offering price of $16.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol “ADMS” on April 10, 2014. Adamas had […]
Quick update: The IBB – Negative Divergence
iShares Nasdaq Biotechnology (IBB) – Nasdaq As tweeted several time last and early this week, signs of weakness in the IBB Signs of weakness in the $IBB ..Start forming a Bearish “Rising Wedge” ..only if breaking down the lower line & 50MA pic.twitter.com/MPmn1DNF2T — Joe (@GantosJ) February 2, 2015 The “Rising Wedge” is a bearish pattern, […]
IBB – XLV Biotech Sector Post JP-Morgan Conference
iShares Nasdaq Biotechnology (IBB) – Nasdaq Health Care Select Sector SPDR ETF (XLV)–NYSE The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as the biotech barometer and choose the XLV as a hedge to our biotech portfolio . As mentioned […]
BMY – A Bull Flag Breakout or A Head Fake
Bristol-Myers Squibb Company (BMY) -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach at least the last 52-weeks high at $57.49 . But BMY’s price spike even higher reaching new 52-weeks high $59.03 on October 30th after reporting […]
Caution, SPY – Forming A Rare Tri-Star Pattern
SPDR S&P 500 ETF (SPY) –NYSE The SPY had an extreme price action during the last two months after reaching the All-Time-High 201.90 points on September 19th, followed by a deep correction, reaching the low of 181.92 on October 15th where the bulls came back to buy the dip and pushing the price back to […]
MRK – A Falling Knife Or a Golden Opportunity
Merck & Co. Inc. (MRK) -NYSE Many speculation going around the huge drop in MRK’s share price in just one week, dropping from the $60.18 (closing on 10/08) to reach the low of $52.49 today, but bouncing back sharply to trade around the support line $53.44. Some speculation of De-risking as we get closer to […]
CNAT – A Quick Chart Update
Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line as mentioned several time at Chimera’s twitter private feed and was moving side way in a consolidation mode for two weeks. J: $CNAT bouncing 8.5% […]
SRPT- A Squeeze In The Making
Sarepta Therapeutics, Inc. (SRPT)-Nasdaq Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan Stanley Healthcare Conference on September 10th. We received guidance in April from the FDA that outlined a very clear path-forward, which resulted in a plan […]
Merck – Preparing For The Next Move
Merck & Co. Inc. (MRK) -NYSE Lately, Merck was under the spot light after Idenix Pharmaceuticals deal, paying $3.85 Billion more than triple Idenix’s market capitalization before the deal , and to take part of the Hepatitis C battle, one of the hottest areas of drug development along with GILD, ABBV and BMY. But the […]
SPY – A Quick Look at The Broader Market
SPDR S&P 500 (SPY) –NYSE Yesterday we got a sharp turn in the SP-500 as the daily chart of the SPY (S&P 500 ETF) drops sharply and breaks down the uptrend channel for the first time after two months of uptrend within the channel. Breaking down the 50-Day moving average as well which was supposed be […]
Tekmira – Is It The Bottom Yet
Tekmira Pharmaceuticals Corp (TKMR) –Nasdaq Tekmira is the new “fallen star” after the wild run started Jan 07th, 2014 from $7.66, and reaching the all time high $31.48 mid March. But that was the inflection point as well, the price start dropping fast with no stops or even real technical correction, reaching the support […]
BMY – In The Inflection Point
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $41.11 in late August 2013 to reach a new 12 years high $57.49 in early March 2014, as investors were anticipating the anti PD-1 data coming at ASCO-2014 and with high expectations for BMY’s data of […]
RTRX – In a Consolidation Mode
Retrophin, Inc. (RTRX) –Nasdaq During the last 13 trading days, RTRX trading along the 200-Day moving avarage (red line) with small candlestick (doji) on a descending volume confirming the consolidation mode. The MACD moving to the positive territory along with the RSI positive momentum as well. the next resistance line is the 50-Day moving average […]
IBB – In the Decision Zone
iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as the biotech barometer. And as mentioned in my last report ” IBB – Biotech Sector in The Despondency Point ” the emotions are playing an important role […]
Progenics: Consolidation Ahead of the AdCom
Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq Relistor has been approved by regulatory authorities in the U.S., countries in the E.U., Canada and Australia since 2008 for treatment of OIC in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient. On May 09, 2014 Progenics announced during the 1Q earnings call an FDA Advisory Committee […]
IBB – Biotech Sector in The Despondency Point
iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as the biotech barometer, which has suffered lately from an over exposure. It has been mentioned nonstop on any financial TV programs or investors reports, trying […]
Pfizer – Technical points to watch
Pfizer Inc. (PFE) -NYSE A long awaited date from Pfizer revealed on Sunday April 04, 2014 at the AACR-2014. Pfizer announced detailed results from the PALOMA-1 study, a randomized Phase 2 study of palbociclib in combination with letrozole. PALOMA-1 achieved its primary endpoint by significantly prolonging progression-free survival (PFS) compared with letrozole alone in post-menopausal women with […]
